NURO vs. ALUR, SURG, MHUA, OM, LFWD, FEMY, DRIO, MDAI, STIM, and PXDT
Should you be buying NeuroMetrix stock or one of its competitors? The main competitors of NeuroMetrix include Allurion Technologies (ALUR), SurgePays (SURG), Meihua International Medical Technologies (MHUA), Outset Medical (OM), ReWalk Robotics (LFWD), Femasys (FEMY), DarioHealth (DRIO), Spectral AI (MDAI), Neuronetics (STIM), and Pixie Dust Technologies (PXDT). These companies are all part of the "medical equipment" industry.
NeuroMetrix (NASDAQ:NURO) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, community ranking, earnings, profitability, risk, media sentiment and valuation.
NeuroMetrix received 278 more outperform votes than Allurion Technologies when rated by MarketBeat users. However, 100.00% of users gave Allurion Technologies an outperform vote while only 59.92% of users gave NeuroMetrix an outperform vote.
In the previous week, Allurion Technologies had 2 more articles in the media than NeuroMetrix. MarketBeat recorded 5 mentions for Allurion Technologies and 3 mentions for NeuroMetrix. NeuroMetrix's average media sentiment score of 0.30 beat Allurion Technologies' score of 0.17 indicating that NeuroMetrix is being referred to more favorably in the media.
Allurion Technologies has a consensus price target of $3.17, indicating a potential upside of 414.82%. Given Allurion Technologies' higher probable upside, analysts plainly believe Allurion Technologies is more favorable than NeuroMetrix.
NeuroMetrix has higher earnings, but lower revenue than Allurion Technologies. NeuroMetrix is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.
NeuroMetrix has a beta of 2.28, suggesting that its share price is 128% more volatile than the S&P 500. Comparatively, Allurion Technologies has a beta of -0.33, suggesting that its share price is 133% less volatile than the S&P 500.
19.4% of NeuroMetrix shares are owned by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are owned by institutional investors. 7.3% of NeuroMetrix shares are owned by company insiders. Comparatively, 20.0% of Allurion Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Allurion Technologies has a net margin of -78.56% compared to NeuroMetrix's net margin of -181.04%. Allurion Technologies' return on equity of 0.00% beat NeuroMetrix's return on equity.
Summary
Allurion Technologies beats NeuroMetrix on 12 of the 18 factors compared between the two stocks.
Get NeuroMetrix News Delivered to You Automatically
Sign up to receive the latest news and ratings for NURO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NURO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroMetrix Competitors List
Related Companies and Tools
Free NURO Stock Alerts